Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Afumati – page 25

363 clinical trials in Afumati, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Afumati at a glance
363
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

363 trials in Afumati

Open in trial search

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic hepatitis B+1

Not recruiting

Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:GlaxoSmithKline Biologicals

Study to Compare Fianlimab and Cemiplimab Combination with Cemiplimab Alone for Adults with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Vudalimab or Pembrolizumab with Chemotherapy for Advanced Non-small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Xencor Inc.

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Afumati

What the registry says about research in the country

01 Autoimmune Research

Innovative clinical research focusing on Systemic Lupus Erythematosus (SLE), evaluating new therapeutic approaches with ianalumab in combination with standard treatments. The trials aim to improve patient response rates and disease management outcomes.

  • SLE Treatment Development
  • Monthly Subcutaneous Therapy
  • Response Index Assessment

These studies represent significant advancement in autoimmune disease research.

02 Cardiovascular Prevention

Groundbreaking research in atherosclerotic cardiovascular disease (ASCVD) prevention, investigating inclisiran's potential in reducing major adverse cardiovascular events in high-risk patients.

  • Primary ASCVD Prevention
  • Cardiovascular Risk Reduction
  • Major Adverse Events Prevention

This research aims to establish new standards in preventive cardiology.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.